Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP)
Depression in Adolescence

About this trial
This is an interventional treatment trial for Depression in Adolescence focused on measuring Depression, Adolescence, SSRI, Antidepressant, Pharmacogenetics
Eligibility Criteria
Inclusion Criteria: Age 12-17 Depression as the primary concern, confirmed by the treating physician QIDS-A17 score greater than or equal to 11 indicating moderate-to-severe symptoms Prior failure of fluoxetine therapy due to inefficacy or intolerance Intention to start a new SSRI English fluency Exclusion Criteria: Co-occurring psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability A score of 2 or 3 on suicide item 13 of the QIDS-A17 High-risk alcohol or substance use (excluding cannabis and tobacco) as indicated by a score of monthly or more on the S2BI History of non-response to 3 or more antidepressants (including fluoxetine, i.e. failure of fluoxetine and two other agents) as confirmed by the treating physician Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change these therapies during study participation History of liver or hematopoietic cell transplant History of CYP2B6, CYP2C19, or CYP2D6 testing
Sites / Locations
- University of Calgary
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Pharmacogenetic (PGx)-Guided
Guidelines for Adolescent Depression in Primary Care (GLAD-PC)-Guided
Participants and their physician will receive a one-time prescribing report after completing baseline for second-line selective serotonin reuptake inhibitors with dosing information based on CYP2B6, CYP2C19, and CYP2D6 genotype data.
Participants and their physician will receive a one-time prescribing report after completing baseline for second-line selective serotonin reuptake inhibitors based on GLAD-PC dosing guidelines.